RGNXW Financials 07/16/2014 00:36:02 RegeneRx Bio

RGNXW Financials 07/16/2014 00:36:02
RegeneRx Biopharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 29 1,343 1,512 850
Cost of Revenue - - - -
Gross Profit 29 1,343 1,512 850
Operating Expenses
Research and Development 189 1,162 5,067 2,708
Sales, General and Admin. 755 1,022 2,456 3,174
Non-Recurring Items - - - -
Other - - - -
Operating Income (914) (841) (6,012) (5,032)
Income From Continuing Operations
Add'l Income/Expense Items 344 - 4 8
Earnings Before Interest and Tax (570) (841) (6,007) (5,024)
Interest Expense 101 6 - -
Earnings Before Tax (671) (847) (6,007) (5,024)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (671) (847) (6,007) (5,024)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (671) (847) (6,007) (5,024)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (671) (847) (6,007) (5,024)